Pancreatic Cancer Research

ResearcherUniversity of KochiActive in the last 2 years

Kazuhiro Hanazaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7986-6146; OpenAlex author ID A5055865253. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 2)
Trials
1
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2003: 1 trial · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 9

  1. Impact of the COVID-19 pandemic on short-term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Cl… Co-author DOI 10.1002/ags3.12798↗
  2. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell car… Co-author DOI 10.1016/j.neo.2021.07.006↗
  3. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0335↗
  4. Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2016.07.002↗
  5. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells. Co-author DOI 10.1186/s13046-016-0466-0↗
  6. Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines. Last author DOI 10.21873/anticanres.11197↗
  7. Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity. Co-author DOI 10.1097/mpa.0000000000000270↗
  8. IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. Co-author DOI 10.18632/oncotarget.2257↗
  9. Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer. Last author DOI 10.3892/ol.2014.2101↗

Trials 1

  1. Benefit of Roux-en-Y (R-Y) Reconstruction After Pancreaticoduodenectomy Study chair NCT00906802↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshiji Saibara · 5 shared papers, 2014–2016 · strength 0.25
  2. Shigehiro Tsujii · 2 shared papers, 2021 · strength 0.25
  3. Sunao Uemura · 2 shared papers, 2021 · strength 0.25
  4. Tetsuji Naka · 2 shared papers, 2021 · strength 0.25
  5. Mutsuo Furihata · 4 shared papers, 2014–2016 · strength 0.22
  6. Keisuke Taniuchi · 4 shared papers, 2014–2016 · strength 0.22
  7. Masaki Mori · 1 shared paper, 2024 · strength 0.18
  8. Yasuyuki Seto · 1 shared paper, 2024 · strength 0.18
  9. Hideki Ueno · 1 shared paper, 2024 · strength 0.18
  10. Yutaka Nakano · 1 shared paper, 2024 · strength 0.18
  11. Yusuke Takemura · 1 shared paper, 2024 · strength 0.18
  12. Akinobu Taketomi · 1 shared paper, 2024 · strength 0.18
  13. Yuko Kitagawa · 1 shared paper, 2024 · strength 0.18
  14. Eri Munekage · 2 shared papers, 2016–2021 · strength 0.18
  15. Yuka Takezaki · 1 shared paper, 2016 · strength 0.06
  16. Makiko Tsuboi · 1 shared paper, 2016 · strength 0.05
  17. Aki Tanouchi · 1 shared paper, 2016 · strength 0.05
  18. Akihito Nishioka · 1 shared paper, 2014 · strength 0.04
  19. Takehiro Okabayashi · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.